🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. SECRET-HF: Treatment of Non-ischemic Dilated Cardiomyopathies by Intravenous Infusions of the Extracellular Vesicle-Enriched Secretome of Cardiovascular Progenitor Cells

    Pari Pharma GmbH

    Non-ischemic Dilated Cardiomyopathies

    phase 1 other active

    1 trial

  2. SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo

    Silence Therapeutics plc

    Non-transfusion-dependent Thalassemia

    phase 1 small molecule terminated

    1 trial

  3. SPECT/CT imaging of FPI-2505 in patients with solid tumours; a phase 0 molecular imaging basket trial (SCOPE-study).

    Lacuna Pharma Pty Ltd

    small cell lung cancer, non-smallcell lung cancer, colorectal cancer, breast cancer, Pancreatic cancer and gastric cancer

    phase 1 other active

    1 trial

  4. SSGJ-613

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Arthritis, Gouty

    phase 1 small molecule active

    1 trial

  5. SSS11

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gout

    phase 1 mab active

    1 trial

  6. STRATIFY; Near-infrared fluorescence molecular imaging of adalimumab-800CW to elucidate the drug distribution throughout inflamed tissue in inflammatory bowel disease and rheumatoid arthritis

    Disc Medicine

    Crohn's disease, Spondyloarthritis, Rheumatoid arthritis, Ulcerative colitis

    phase 1 other active

    1 trial

  7. STRO-004

    SUTRO BIOPHARMA, INC.

    Head and Neck Squamous Cell Carcinoma HNSCC

    phase 1 small molecule active

    1 trial

  8. Safety and Early Signs of Efficacy of IL12-L19L19

    Philogen S.p.A.

    Advanced or metastatic carcinomas after previous immune checkpoint blockade therapy

    phase 1 other active

    1 trial

  9. Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patients

    Lacuna Pharma Pty Ltd

    A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s disease

    phase 1 other active

    1 trial

  10. Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous multiple rising doses of BI 765250 versus placebo in trial participants with moderate to severe plaque psoriasis (double-blind, randomised, placebo-controlled, parallel-group design)

    Boehringer Ingelheim

    Plaque psoriasis

    phase 1 other active

    1 trial

  11. Sapropterin dihydrochloride tablets

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 1 small molecule active

    1 trial

  12. Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 1 small molecule active

    1 trial

  13. Single dose intravenous injection of BBM 002

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hemophilia A

    phase 1 gene therapy active

    1 trial

  14. Single microdose trial - CXCR4 PET tracer - Pharmacokinetics and pharmacodynamics of [68Ga]Ga-R54, a CXCR4-targeted radiopharmaceutical in patients with advanced solid tumors.

    Fondazione Telethon ETS

    Advanced solid neoplasm (breast, lung, colon, ovary, pancreas) characterized by positive CXCR4 expression by immunohistochemistry

    phase 1 other active

    1 trial

  15. Sinovac PCV24 formulation 1

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Disease

    phase 1 mab completed

    2 trials

  16. Stem Cell

    EuroGen Pharmaceuticals Ltd

    Neurological; Disorder, Nervous System

    phase 1 mab terminated

    1 trial

  17. Study of REGN6569 and Cemiplimab in Adult Patients with Advanced Solid Tumor Malignancies

    Lacuna Pharma Pty Ltd

    Squamous Cell Carcinoma of Head and Neck

    phase 1 other active

    1 trial

  18. Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors.

    Novartis Pharmaceuticals

    Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma

    phase 1 other active

    1 trial

  19. Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

    AbbVie Deutschland GmbH & Co. KG

    Non-Hodgkin's Lymphoma

    phase 1 other active

    1 trial

  20. Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

    AbbVie Deutschland GmbH & Co. KG

    Select B-Cell malignancies.

    phase 1 other active

    1 trial

  21. Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer patients who underwent surgery and adjuvant chemotherapy

    Samsung Bioepis NL B.V.

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  22. Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

    Amgen

    Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

    phase 1 other active

    1 trial

  23. Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.

    Daiichi Sankyo

    Advanced Solid Tumor

    phase 1 other active

    1 trial

  24. Switch active lifestyles brought to you by MediaWise

    Lxo Ireland Designated Activity Company

    Overweight

    phase 1 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources